帕金森病中的共价抑制剂:神经保护性干预的分子向策略
Devadharuna Mohan1, Raghul Venkatesan1, Amarjith Thiyyar Kandy1
1Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.
Molecular and cellular neurosciences
|September 11, 2025
概括
性抑制剂通过向蛋白质聚合和神经炎症等关键机制,为帕金森病 (PD) 提供了一个有前途的治疗策略. 新兴的共价降解剂增强了这种持续神经保护和改善PD治疗的潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 帕金森病 (PD) 涉及多巴胺基神经元损失,蛋白质聚合和神经炎症,目前的疗法仅提供症状缓解.
- 与位形成不可逆转的键的共价抑制剂,为PD提供了多因素的治疗方法.
研究的目的:
- 审查针对关键PD分子机制的新兴共价抑制剂.
- 讨论结构导向设计,弹头化学和用于增强神经保护的新型抑制方式.
- 评估临床前进展,临床挑战和PD治疗的下一代共价策略.
主要方法:
- 对PD的共价抑制剂的实验和计算发现的叙述性综述.
- 对结构导向药物设计,弹头化学和抑制方式的分析.
- 对向的共价降解剂,PROTACs和双功能共价降解剂的评估.
主要成果:
- 协同抑制剂向关键的PD途径,包括α-synuclein聚合,LRRK2过活,MAO-B功能障碍,GSTP1-介导的氧化应激,和Nrf2调制.
- 新兴的向共价降解剂促进选择性蛋白质降解,扩大治疗选择超出功能抑制.
- 共价方法对持续的PD干预有希望,目前正在进行的研究解决了选择性和血脑屏障透的问题.
结论:
- 共价抑制剂和降解剂是有针对性的疾病修饰帕金森病干预措施的领先候选人.
- 下一代策略,如共价PROTACs和双功能降解剂,旨在优化治疗疗效和克服发展障碍.
- 进一步的研究至关重要,以提高选择性,血脑屏障的透率,并最大限度地减少非目标效应,以获得成功的临床转化.
相关概念视频
01:24Parkinson's Disease: Treatment
995
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
995
01:15Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
01:37Neural Regulation
43.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.2K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
834
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
834
01:22Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
01:29Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K